FIGURE 2. Relative stereochemistry of 3 and 6.
H2O was gel-filtered on Sephadex G-10 with H2O. The active
fraction was further separated by two rounds of HPLC on a
phenylhexyl column, first using a gradient elution of 0-50%
MeCN containing 0.05% TFA and then isocratic elution with 9%
MeCN containing 0.05% TFA to afford compound 1 (638.2 mg).
The fractions eluted with 20% and 50% MeOH from ODS flash
chromatography were combined and gel-filtered on Sephadex
LH-20 with MeOH/H2O (50:50). The active fractions were
separated by centrifugal partition chromatography [rotation,
1700 rpm; mobile phase, n-BuOH/MeOH/H2O (4:1:5); flow rate,
3 mL/min; ascending mode] to afford 35 fractions (15 mL each)
and additional 16 fractions by a reversed elution. The active
fractions eluted between 135 and 210 mL were separated by
ODS HPLC (gradient elution of 0-80% MeOH containing 0.05%
TFA) followed by reversed-phase HPLC on a C30 column (23%
MeCN containing 0.05% TFA) to afford compound 3 (13.2 mg).
Another fraction from the second ODS HPLC was finally purified
by reversed-phase HPLC on a phenylhexyl column (25% MeCN
containing 0.05% TFA) to furnish compound 2 (1.0 mg).
11-N-Methylmoloka′iamine (1): white powder; UV (MeOH)
λmax 277 (ꢀ 340), 284 nm (330); IR νmax (film) 3850, 3732, 3356,
2943, 2832, 1682, 1455, 1117, 1033 cm-1; HRFABMS m/z
366.9831 (M + H)+ (calcd for C12H19ON279Br81Br, ∆ -1.3 mmu);
1H NMR (600 MHz, CD3OD) δ 7.53 (s, 2H, H-6, 8), δ 4.08 (t, J
) 5.8 Hz, 2H, H-3), δ 3.26 (t, J ) 7.5 Hz, 2H, H-1), δ 3.19 (t, J
) 7.7 Hz, 2H, H-11), δ 2.90 (t, J ) 7.7 Hz, 2H, H-10), δ 2.67 (s,
3H, H-12), δ 2.16 (quint, J ) 5.8, 7.5 Hz, 2H, H-2); 13C NMR
(150 MHz, CD3OD) δ 153.1 (C-4), δ 137.4 (C-7), δ 134.5 (C-6, 8),
δ 119.3 (C-5, 9), δ 71.7 (C-3), δ 50.7 (C-11), δ 38.8 (C-1), δ 33.7
(C-12), δ 31.8 (C-10), δ 29.2 (C-2).
4. The product was used in the next reaction without purifica-
tion. 4: 1H NMR (600 MHz, CD3OD) δ 7.85 (dd, J ) 5.0, 3.1 Hz,
2H), δ 7.81 (dd, J ) 5.0, 3.1 Hz, 2H), δ 7.53 (s, 2H), δ 4.07 (t, J
) 6.2 Hz, 2H), δ 3.95 (t, J ) 7.3 Hz, 2H), δ 3.22 (t, J ) 7.7 Hz,
2H), δ 2.92 (t, J ) 7.7 Hz, 2H), δ 2.70 (s, 3H), δ 2.25 (quint, J )
6.2, 7.3 Hz, 2H).
Preparation of Cyanamide 5. To a mixture of 4 prepared
as described above and NaHCO3 (42.0 mg, 0.5 mmol) in EtOH
(2.5 mL) was added dropwise a solution of CNBr (53.0 mg, 0.5
mmol) in EtOH (2.5 mL) at rt. After stirring for 12 h at rt, the
reaction mixture was evaporated, suspended in H2O, and
extracted with EtOAc to give 5: 1H NMR (600 MHz, CD3OD) δ
7.85 (dd, J ) 5.4, 3.1 Hz, 2H), δ 7.80 (dd, J ) 5.4, 3.1 Hz, 2H),
δ 7.51 (s, 2H), δ 4.07 (t, J ) 6.2 Hz, 2H), δ 3.96 (t, J ) 7.3 Hz,
2H), δ 3.26 (t, J ) 7.1 Hz, 2H), δ 2.86 (t, J ) 7.1 Hz, 2H), δ 2.84
(s, 3H), δ 2.24 (tt, J ) 6.2, 7.3 Hz, 2H).
Preparation of 2. A solution of hydrazine monohydrate (32.0
mg, 1.0 mmol) in EtOH (2.0 mL) was added dropwisely to a
solution of 5 in EtOH (5.0 mL) at rt. The reaction mixture was
stirred for 15 h at rt and evaporated. The residue was purified
by reversed-phase HPLC on a phenylhexyl column (25% MeCN
containing 0.05% TFA) to afford 2 (19.5 mg, 31.4%) whose 1H
NMR and FAB mass spectra were indistinguishable from those
of the natural product.
Preparation of the Diol 6. A solution of 3 (5.0 mg, 7.7 µmol)
in MeOH (1 mL) was added to Na(OAc)3BH (31 mg, 146 µmol)
at rt. The mixture was stirred for 1 h at rt and evaporated. The
residue was purified by ODS HPLC (gradient elution of 5-35%
MeCN containing 0.05% TFA) to afford 6 (1.5 mg, 30.0%) and
unreacted 3 (3.5 mg). 6: 1H NMR (600 MHz, CD3OD) δ 7.86
(br, 1H), δ 7.53 (s, 2H), δ 4.42 (br, 1H), δ 4.20 (s, 1H), δ 4.11 (br,
1H), δ 4.07 (br, 2H), δ 3.85 (br, 2H), δ 3.22 (t, 6.9 Hz, 2H), δ
3.22 (overlapped, 1H), δ 3.12 (br, 1H), δ 2.92 (t, 6.9 Hz, 2H), δ
11-N-Cyano-11-N-methylmoloka′iamine (2): colorless solid;
UV (MeOH) λmax 277 (ꢀ 440), 284 nm (440); IR νmax (film) 3418,
2210, 1652, 1457, 1203, 1140 cm-1; HRFABMS m/z 391.9788
(M + H)+ (calcd for C13H18ON379Br81Br, ∆ -0.8 mmu); 1H NMR
(600 MHz, CD3OD) δ 7.56 (s, 2H, H-6, 8), δ 4.13 (t, J ) 5.8 Hz,
2H, H-3), δ 3.31 (t, J ) 7.1 Hz, 2H, H-1), δ 3.27 (t, J ) 6.9 Hz,
2H, H-11), δ 2.89 (t, J ) 6.9 Hz, 2H, H-10), δ 2.86 (s, 3H, H-12),
δ 2.20 (quint, J ) 5.8, 7.1 Hz, 2H, H-2); 13C NMR (150 MHz,
CD3OD) δ 152.6 (C-4), δ 139.2 (C-7), δ 134.5 (C-6, 8), δ 119.0
(C-5, 9), δ 118.8 (N-CN), δ 71.6 (C-3), δ 54.6 (C-11), δ 39.1
(C-12), δ 38.9 (C-1), δ 33.1 (C-10), δ 29.0 (C-2).
2.84 (br, 1H), δ 2.80 (br, 1H), δ 2.70 (s, 3H), δ 2.20 (br, 2H); 13
C
NMR (HSQC, CD3OD) δ 156.0 (C-1′), δ 133.0 (C-6, 8), δ 78.5
(C-11′), δ 69.9 (C-3), δ 67.3 (C-9′), δ 52.5 (C-7′), δ 52.2 (C-8′), δ
51.5 (C-10′), δ 49.2 (C-11), δ 48.2 (C-4′), δ 48.0 (C-5′), δ 47.7
(C-1), δ 33.2 (C-12), δ 30.6 (C-10), δ 30.1 (C-2).
Acknowledgment. Thanks are due to the crew of
R/V Toyoshio-maru for assistance in collecting the
sponge. This work was partly supported by a Grant-in-
Aid from the Japan Society for the Promotion of Science.
Kuchinoenamine (3): colorless solid; [R]21 +21 (c 0.05,
D
MeOH); UV (MeOH) λmax 244 (ꢀ 8620), 310 nm (12730); IR νmax
(film) 3440, 1757, 1730, 1682, 1614, 1556, 1471, 1257, 1203,
1136, 721 cm-1; HRFABMS m/z 650.9357 (M + H)+ (calcd for
C
23H26O5N279Br81Br2, ∆ +0.6 mmu); 1H and 13C NMR data, see
Supporting Information Available: General experimen-
tal procedure; 1H NMR, 13C NMR, COSY, HMBC, and
HMQC spectra of 1-3 in CD3OD; HOHAHA spectrum of 3 in
CD3OD; NOESY spectrum of 3 in CD3OH. This material is
Table 1.
Preparation of Phthalimide 4. A solution of N-carboeth-
oxyphthalimide (65.7 mg, 0.3 mmol) in THF/H2O (4:1, 2.0 mL)
was added to a solution of compound 1 (59.6 mg, 0.1 mmol) and
Na2CO3 (63.6 mg, 0.6 mmol) in THF/H2O (4:1, 2.0 mL) at rt.
The mixture was stirred at rt for 30 min to afford phtahlimide
JO048203J
1896 J. Org. Chem., Vol. 70, No. 5, 2005